Nebokitug

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameNebokitug
Drug Alias NameCM-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionChemokine (C-C Motif) Ligand 24 inhibitors
TargetsChemokine (C-C Motif) Ligand 24
Therapy Area/IndicationsScleroderma, SystemicMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, Sclerosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesChemomab Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChemomab
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, Sclerosing
Inactive IndicationsScleroderma, Systemic

Other Information

ATC CodeN/A
Related LinksN/A